Beijing Avistone Biotechnology Co Ltd has gained approval from the Chinese National Medical Products Administration to extend the application of vebreltinib for treating adult patients
Hyundai Bioscience made headlines on April th with its breakthrough announcement regarding the development of an oral anticancer drug targeting patients with intractable cancers
Apollomics Inc has announced a significant development regarding vebreltinib in China The National Medical Products Administration has granted approval to Avistone Biotechnology Co Ltd
Biolojic Design a biotech company specializing in AIdriven antibody innovation announced that Nektar has exercised its license option to develop a program resulting from their collaborative research started in
Amneal Pharmaceuticals Inc has unveiled its Over the Counter Naloxone Hydrochloride Nasal Spray USP mg after securing Abbreviated New Drug Application approval from the US Food and Drug Administration
Junshi Biosciences a leading biopharmaceutical company dedicated to innovative therapies has announced the acceptance of its New Drug Application by the Drug Office of the Hong Kong Special Administrative Region This NDA relates to toripalimab proposed for use in combination
PRISM BioLab Co Ltd a leading discovery and development biotechnology company designing small molecule inhibitors of proteinprotein interaction targets today announced that it has entered into a targetexclusive research and licensing agreement with ONO PHARMACEUTICAL CO LTD
Medivir AB a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need announced today that its selective cathepsin K inhibitor MIV has been granted
Our customers depend on the high performance and reliability of the plates used in their highthroughput processes However increased throughput results in a higher carbon footprint
Alkermes plc today announced initiation of the Vibrance study a phase clinical trial evaluating the safety and efficacy of ALKS compared to placebo in patients with narcolepsy type ALKS is the companys novel
Atom Bioscience a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases has begun enrolling patients
Cullinan Therapeutics Inc a biopharmaceutical company focused on modalityagnostic targeted therapies today announced that clinical data from its Phase trial of CLN in patients with advanced solid tumors
Boston, MA, USA
Bergamo, Italy
Boston, MA, USA
Boston, MA, USA
Chicago, Illinois, USA
Arizona,USA
Boston, MA, USA
Research Scholar, Sigma Institute of Pharmacy
Research Scholar, Sigma Institute of Pharmacy
Professor, Sigma Institute of Pharmacy
Doctorate of Medicine in Pharmacology JIPMER Puducherry
Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companiesThe successful introduction of commercial lipidic formulations of cyclosporine as Sandimmune in followed by its reformulation as Neoral has raised interest of the lipidbased drug delivery technology over the past two decades With a greater understanding of the various functions lipids may have in boosting oral bioavailability
COVID vaccines based on the Spike protein of SARSCoV have been developed that appear to be largely successful in stopping infection However therapeutics that can help manage the disease are still required until immunity has been achieved globally
AbstractHydrazine NH is a known genotoxic impurity that typically needs to be controlled down to low ppm level in pharmaceutical development Hydrazine however is a challenging molecule to analyze using conventional analytical techniques due to its physical and chemical properties eg lack of chromophore absence of any carbon atom low molecular weigh
Fosun Pharma has developed a groundbreaking MEK inhibitor known as FCN tablet with the aim of treating adult patients suffering from inoperable or postoperative residualrecurrent NFassociated plexiform neurofibromas
SummaryMany scientific enterprises find themselves in need of a Laboratory Information Management System LIMS to replace an incumbent system whether an existing commercial application an amalgam of systems or an inhouse solution Once the decision has been made the selection and deployment of a new LIMS should move quickly and decisively This white pap
Approximately million people worldwide are living with a rare disease and about half of those affected by rare diseases are children
Although less well known than other drug development phases human factors engineering HFE is critical to meeting regulatory expectations for drugdevic...
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Many advanced largescale AI initiatives still need to be proved successful in Pharma
Singapore has had a multidecade longterm vision for building a worldclass biomedical cluster